Here are four things to know:
1. Goldman, Sachs & Co. will continue to help the company evaluate its strategic alternatives to bolster stockholder value.
2. At this time, Accretive Health has not chosen a specific strategic transaction to drive long term growth and financial performance.
3. The company has not set a time limit for the review, and does not assert that a strategic alternative will be chosen at the end of the process.
4. Accretive Health will not address the end of the review unless it is chooses a transaction with the help of Goldman, Sachs & Co.
Recent articles:
New Jersey Physician sentenced for bribery scheme — 8 facts
Medicare trust fund has money for 15 more years: 5 interesting points
11 things to know about robotic surgery
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
